Recent advances in HER2 positive breast cancer epigenetics: Susceptibility and therapeutic strategies
HER2 amplification/overexpression accounts for aggressive clinical features of HER2
positive breast cancer. Epigenetic changes including DNA methylation, histone …
positive breast cancer. Epigenetic changes including DNA methylation, histone …
Hey factors at the crossroad of tumorigenesis and clinical therapeutic modulation of hey for anticancer treatment
Hairy and Enhancer-of-split related with YRPW motif (Hey) transcription factors are important
regulators of stem cell embryogenesis. Clinical relevance shows that they are also highly …
regulators of stem cell embryogenesis. Clinical relevance shows that they are also highly …
HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors
Histone deacetylase inhibitors (HDACi) may engage host immunity as one basis for their
antitumor effects. Herein, we demonstrate an application of this concept using the HDACi …
antitumor effects. Herein, we demonstrate an application of this concept using the HDACi …
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall …
Purpose Suberoylanilide hydroxamic acid (SAHA; vorinostat), a small molecule inhibitor of
histone deacetylase, attenuates signaling pathways known to confer trastuzumab …
histone deacetylase, attenuates signaling pathways known to confer trastuzumab …
[HTML][HTML] Molecular mechanisms underlying the filtration bleb-maintaining effects of suberoylanilide hydroxamic acid (SAHA)
A Futakuchi, T Inoue, T Fujimoto… - … & Visual Science, 2017 - iovs.arvojournals.org
Purpose: Suberoylanilide hydroxamic acid (SAHA) has been shown to support the
maintenance of experimental filtration blebs in animal models. This study was performed to …
maintenance of experimental filtration blebs in animal models. This study was performed to …
[HTML][HTML] Effects of histone deacetylase inhibitor panobinostat (LBH589) on bone marrow mononuclear cells of relapsed or refractory multiple myeloma patients and its …
Y Ma, W Liu, L Zhang, G Jia - Medical Science Monitor …, 2017 - ncbi.nlm.nih.gov
Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear
Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms - PMC Back to …
Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms - PMC Back to …
Generation and assessment of fusions between HDACi and TKi
S Mahboobi, B Pilsl, A Sellmer - HDAC/HAT Function Assessment and …, 2017 - Springer
Chimeric compounds combine the structural features of inhibitors of histone deacetylases
(HDACi) and tyrosine kinase inhibitors (TKi), and therefore unite the effects of a dual …
(HDACi) and tyrosine kinase inhibitors (TKi), and therefore unite the effects of a dual …
[PDF][PDF] A Phase I/II Study of MLN9708 (Ixazomib) in Combination with Panobinostat and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
FJ Reu, J Valent, E Malek - cdn.clinicaltrials.gov
Clinical study protocol Page 1 CASE 4A13 A9 04/03/2017 Case CCC Study: CASE 4A13
Clinical Trial Protocol Number CLBH589DUS92T Title: A Phase I/II Study of MLN9708 (Ixazomib) …
Clinical Trial Protocol Number CLBH589DUS92T Title: A Phase I/II Study of MLN9708 (Ixazomib) …
[引用][C] Clinical Trial Protocol Number CLBH589DUS97T
J Song, K Shain, R Baz, L Perez, JL Ochoa-Bayona… - 2017